Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Will Trial its PD-1 With Xuanzhu’s HER-2 ADC for Solid Tumor Cancers

publication date: Dec 28, 2023

Suzhou Innovent announced a clinical trial collaboration with Xuanzhu Biopharma that will pair Innovent’s sintilimab, an approved PD-1 inhibitor, with Xuanzhu’s novel HER-2 bispecific ADC for solid tumor cancers. The Xuanzhu candidate, KM-501, is a dual-antibody ADC that targets two different domains of HER2. KM-501 is aimed at advanced/metastatic solid tumors with HER2 positive expression, amplification or mutation, including advanced tumors with low HER2 expression. Xuanzhu will conduct a China Phase Ib clinical study to evaluate the anti-tumor activity and safety of the combination therapy. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital